View in EDS HTML Full Text PDF Full Text

KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.

Saved in:
Bibliographic Details
Title: KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.
Authors: Mizrak Kaya, Dilsa1,2 (AUTHOR), Ma, Yangruijue2,3 (AUTHOR), Demir, Tarik1,3,4 (AUTHOR), Altomare, Nicole J.4,5 (AUTHOR), Kalyan, Aparna1,5 (AUTHOR), Kircher, Sheetal1,5 (AUTHOR), Mulcahy, Mary2,5 (AUTHOR), Benson III, Al B.3,5 (AUTHOR), Chen, Ruohui3,4 (AUTHOR), Mahalingam, Devalingam1,5 (AUTHOR) mahalingam@nm.org
Source: Cancers. Jul2026, Vol. 18 Issue 13, p2037. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20726694
DOI:10.3390/cancers18132037